ABBV Stock Recent News
ABBV LATEST HEADLINES
The topic of passive income is popular these days. Investors, consumers, and many other individuals are curious about any method that can produce income without work.
I present you our framework for buying and selling dividend stocks. It follows our simple motto of buy low, sell high, get paid to wait. Here are 2 brilliant buys and 2 smart sells for Q2 2024.
The big money might be feeling a bit queasy about overexposure to risk-on assets, presenting a framework to follow regarding the best stocks to buy in April. As I've mentioned many times before, technology-related securities saw an outflow recently of $4.4 billion.
The latest trading day saw AbbVie (ABBV) settling at $180.76, representing a -0.74% change from its previous close.
Now that it's focused on just medical technology and pharmaceuticals, Johnson & Johnson's pace of annual dividend raises could accelerate. Medtronic is the largest publicly traded medical device manufacturer, and it offers a 3.3% yield at recent prices.
AbbVie Inc (NYSE:ABBV)'s approximately $137.5 million acquisition of Landos Biopharma is a strategic move by the pharmaceutical research and development firm which has reiterated the potential of novel innovations with high-growth prospects in the small-cap biotech sector. AbbVie, best known for producing rheumatoid arthritis and Crohn's Disease medication Humira, on Monday announced the deal which will bolster its portfolio of drug candidates for inflammatory and autoimmune diseases.
AbbVie (ABBV) offers to buy Landos Biopharma (LABP) to boost its portfolio in inflammatory and autoimmune disease drugs.
AbbVie (ABBV) closed at $178.53 in the latest trading session, marking a +0.04% move from the prior day.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.